SUGAM Portal: CDSCO Applications for Foreign Pharma/Medical Device Companies

What Is the SUGAM Portal and Why Foreign Companies Must Use It

The SUGAM portal (cdscoonline.gov.in) is the mandatory online platform operated by the Central Drugs Standard Control Organization (CDSCO) under India's Ministry of Health and Family Welfare. Every foreign pharmaceutical company, medical device manufacturer, cosmetics importer, or biologics producer seeking to sell products in India must route their regulatory applications through this portal.

SUGAM replaced the paper-based application system entirely. As of 2025-2026, there is no alternative -- all applications for drug registration certificates, import licenses, clinical trial permissions, and medical device approvals must be submitted digitally through SUGAM. The portal handles applications under the Drugs and Cosmetics Act, 1940 and the Medical Device Rules, 2017.

For foreign companies, the critical constraint is this: you cannot apply directly. Indian regulations require an authorized Indian agent -- either a licensed drug manufacturer or a licensed wholesale dealer in India -- to submit applications on behalf of the foreign manufacturer. Understanding this requirement and the portal mechanics is essential before investing in India's pharma or medical device market, which crossed USD 50 billion in 2025.

SUGAM Portal Registration: Step-by-Step for Foreign Companies

Step 1: Appoint an Indian Authorized Agent

Before touching the SUGAM portal, the foreign company must appoint an Indian authorized agent. This agent must hold one of the following:

• A valid drug manufacturing license issued by a State Drug Licensing Authority, or
• A valid wholesale drug license (Form 20B or Form 21B)

The agent acts as the regulatory interface between the foreign manufacturer and CDSCO. They submit all applications, respond to queries, receive approvals, and are legally responsible for regulatory compliance in India. The appointment is formalized through a Power of Attorney (PoA) notarized and apostilled in the foreign manufacturer's home country.

Step 2: Create an Account on SUGAM

The authorized agent (not the foreign company directly) creates the account:

1. Visit cdscoonline.gov.in and click "New Registration"
2. Select the applicant type: Importer / Agent / Manufacturer
3. Enter company name, registered address, and contact details
4. Upload supporting documents: authorization letter, agent's drug license, ID proof, and undertaking
5. Submit the registration form for CDSCO review

Step 3: Account Approval by CDSCO

CDSCO reviews the registration application and may request clarifications. Once approved, login credentials are issued for accessing the application submission modules. This approval typically takes 7-15 working days. Keep digital copies of all uploaded documents, as the portal does not allow re-downloading after submission.

Drug Registration: Form 40 Application Process

When Form 40 Is Required

Any foreign manufacturer seeking to import drugs (bulk drugs/APIs or finished formulations) into India for sale or distribution must first obtain a Registration Certificate from CDSCO. The application is made in Form 40 under Rule 27 of the Drugs and Cosmetics Rules, 1945.

Form 40 covers:

• Allopathic drugs (new and existing molecules)
• Active Pharmaceutical Ingredients (APIs) / bulk drugs
• Finished formulations for import
• Biologicals and biosimilars (with additional documentation)

Form 40 Application Steps on SUGAM

1. Login and Navigate: Log into SUGAM with approved credentials; select "Drugs" > "Import" > "Registration Certificate (Form 40)"
2. Enter Product Details: Drug name (generic and brand), formulation, dosage form, strength, shelf life, and manufacturing site details
3. Upload Dossier: The Common Technical Document (CTD) format is preferred, including:
   • Certificate of Pharmaceutical Product (CoPP) or Free Sale Certificate from the home country
   • Good Manufacturing Practice (GMP) certificate
   • Certificate of Analysis (CoA) for each product
   • Stability data (as per ICH guidelines)
   • Product samples (sent physically to CDSCO-designated labs)
   • Plant Master File with manufacturing site details
   • Authorization letter / Power of Attorney
4. Pay Fees: USD 10,000 per manufacturing site + USD 5,000 per drug product
5. Submit Application: Finalize and submit for CDSCO review

Form 41: Registration Certificate Issued

Upon successful review, CDSCO issues the Registration Certificate in Form 41. This certificate is valid for 3 years from the date of issue and must be renewed before expiry. The processing timeline is approximately 9-12 months from application to certificate issuance, though this varies based on product complexity and query response speed.

After Registration: Import License

The Registration Certificate (Form 41) alone does not permit import. The authorized agent must separately apply (in Form 8) for an Import License in Form 10 issued by CDSCO (the Central Licensing Authority). This license authorizes the actual import and distribution of the registered drug in India.

Medical Device Import: Form MD-14 Application Process

Medical Device Classification in India

India classifies medical devices into four risk-based classes under the Medical Device Rules, 2017:

Form MD-14 Application Steps

The import license application for medical devices is filed in Form MD-14 on the SUGAM portal (or the dedicated MD portal at cdscomdonline.gov.in for certain device categories):

1. Login and Select Application Type: Choose Form MD-14 for medical device import license
2. Provide Device Details: Device name, intended use, classification (Class A/B/C/D), model numbers, and variants
3. Upload Documents:
   • Device Master File (DMF)
   • Plant Master File (PMF) of the manufacturing facility
   • Free Sale Certificate (FSC) from the country of origin
   • ISO 13485 certificate or CE marking (EU) or 510(k) clearance (US FDA)
   • Declaration of Conformity
   • Clinical investigation data (for Class C and D devices)
   • Power of Attorney from the foreign manufacturer to the Indian agent
   • Labeling and Instructions for Use (IFU)
4. Pay Fees:
   • Class A: Free (self-declaration pathway)
   • Class B: INR 5,000 per site + INR 500 per device
   • Class C: INR 50,000 per site + INR 1,000 per device
   • Class D: Up to USD 4,500 per device
5. Submit for Review: CDSCO reviews documentation and may conduct or request a site inspection of the foreign manufacturing facility

Form MD-15: Import License Issued

Upon approval, CDSCO issues the medical device import license in Form MD-15. Under the Medical Device Rules, 2017, this license is valid in perpetuity, provided a license retention fee is paid before the completion of each 5-year period from the date of issue (failure to pay the retention fee on time cancels the licence). The typical processing timeline:

New Drug Import: Form 44 Application

For new drugs not yet approved in India (new molecules, new formulations, or new indications), the application is filed in Form 44 on the SUGAM portal. This is a more rigorous pathway requiring:

• Complete CTD dossier with Modules 1-5
• Clinical trial data (Indian clinical trials may be required for certain categories)
• Pharmacovigilance plan for post-marketing surveillance
• Risk management documentation

Processing time for Form 44 applications typically ranges from 12-24 months depending on whether Indian clinical trials are mandated. The FDI framework for pharma permits 100% foreign investment under the automatic route for greenfield projects and 74% under automatic route for brownfield (existing) pharma companies.

2026 Regulatory Updates: What Foreign Companies Must Know

30-Day Query Response Rule

In a significant enforcement tightening, CDSCO announced in January 2026 that applications on the SUGAM portal will be rejected if the applicant fails to respond to regulatory queries within 30 days. Previously, applications could remain pending indefinitely. CDSCO specifically targeted applications pending for over two years with three prior reminders, issuing a final warning with rejection by February 14, 2026.

For foreign companies, this means:

• Designate a dedicated regulatory affairs team member to monitor SUGAM daily
• Set up email alerts for query notifications from CDSCO
• Pre-prepare response templates for common CDSCO queries (GMP certificate validity, stability data format, CoA discrepancies)
• Maintain an updated dossier so responses can be submitted within 15 days, well before the 30-day deadline

Dedicated Medical Device Portal

CDSCO has been migrating medical device applications to a dedicated portal at cdscomdonline.gov.in, separate from the main SUGAM portal. Foreign medical device companies should check both portals for their specific device category, as some Class C and D device applications are now processed exclusively through the MD portal.

Clinical Trial Approvals Through SUGAM

When Clinical Trials Are Required

Foreign pharma and medical device companies may need to conduct clinical trials in India before obtaining marketing approval. Under the New Drugs and Clinical Trial Rules, 2019, clinical trials in India are required for:

• New chemical entities not approved in any country
• Drugs approved abroad but seeking first-time approval in India (Phase III trials may be required unless a waiver is granted)
• Class C and D medical devices without predicate approval from a recognized regulatory authority
• Biosimilars requiring comparative clinical studies

Clinical Trial Application on SUGAM

The clinical trial application is submitted through the SUGAM portal using Form CT-04. Required documents include the Investigator's Brochure, Clinical Trial Protocol, Informed Consent Documents, Ethics Committee approval, Investigational Product Dossier, and GMP certificate of the manufacturing facility. CDSCO must grant approval within 90 working days for new drugs and 30 working days for drugs already approved in specified countries (US, UK, EU, Japan, Australia, Canada).

The clinical trial approval fee is INR 50,000 per application. Post-approval, the sponsor must submit safety reports to CDSCO every six months and report Serious Adverse Events (SAEs) within 24 hours through the portal.

Post-Approval Obligations on SUGAM

Pharmacovigilance and Adverse Event Reporting

After receiving the Registration Certificate (Form 41) or Import License (Form MD-15), the foreign company's Indian authorized agent has ongoing obligations that are managed through the SUGAM portal:

• Individual Case Safety Reports (ICSRs): Must be submitted within 15 calendar days for serious and unexpected adverse drug reactions
• Periodic Safety Update Reports (PSURs): Required every 6 months for the first 2 years after approval, then annually for the next 2 years
• Annual Reports: Summary of all adverse events, product complaints, and corrective actions
• Post-Marketing Surveillance (PMS): CDSCO may mandate Phase IV studies as a condition of approval, particularly for drugs approved through expedited pathways

License Renewal Process

Drug Registration Certificates (Form 41) must be renewed every 3 years. Medical Device Import Licenses (Form MD-15) do not expire on a fixed term but require a license retention fee to be paid before the end of each 5-year period to remain valid. The renewal/retention application should be submitted 6 months before the deadline to avoid lapses. Renewal through SUGAM requires updated GMP certificates, stability data, and any new safety information accumulated since the last approval. Operating with an expired or cancelled license constitutes a criminal offense under the Drugs and Cosmetics Act.

Cosmetics Registration Through SUGAM

Foreign cosmetics companies importing into India must also use the SUGAM portal. Under the Drugs and Cosmetics Rules, cosmetics imports require registration with CDSCO. The process is simpler than drug registration but still requires:

• Application in Form 42 for cosmetics registration
• Free Sale Certificate from the country of origin
• Certificate of Analysis for each product
• Product safety assessment data
• Labeling in compliance with Indian regulations (ingredients in descending order, manufacturing and expiry dates, country of origin)

The registration fee for cosmetics is significantly lower than for drugs -- approximately INR 5,000-10,000 per product. Processing takes 3-6 months, and the registration is valid for 3 years.

Navigating SUGAM Portal Technical Issues

The SUGAM portal, while functional, has known technical limitations that foreign companies should anticipate:

• File Size Limits: Individual document uploads are capped at 10-20 MB. Large dossiers must be split across multiple uploads or compressed
• Browser Compatibility: The portal works best with Google Chrome. Firefox and Safari may experience issues with document uploads and payment processing
• Session Timeouts: The portal times out after 15-20 minutes of inactivity. Save drafts frequently, as unsaved data is lost upon timeout
• Payment Gateway: Government fee payments are processed through the SBI Collect system. International credit cards may not work -- use Indian bank accounts or demand drafts as fallback
• Status Tracking: Application status can be tracked using the application reference number. However, status updates may lag by 2-3 weeks behind actual processing progress

Foreign companies should budget for a dedicated regulatory affairs resource or consultancy to manage SUGAM interactions. The combination of portal technicalities, 30-day query deadlines, and the requirement for an Indian authorized agent makes self-service impractical for most foreign manufacturers.

Common Mistakes Foreign Companies Make on SUGAM

• Applying without an authorized agent: Foreign companies cannot create SUGAM accounts directly. The entire application must go through a licensed Indian agent with valid Form 20B/21B wholesale license or manufacturing license
• Submitting expired certificates: GMP certificates, Free Sale Certificates, and ISO certifications must be valid at the time of submission and remain valid through the review period. CDSCO rejects applications with certificates expiring within 6 months
• Ignoring query notifications: The 30-day response window is strict. Missing it results in automatic rejection, and reapplication means starting the entire process (and fee payment) from scratch
• Wrong device classification: Misclassifying a Class C device as Class B to avoid clinical data requirements leads to rejection and potential blacklisting
• Incomplete Power of Attorney: The PoA must be notarized in the country of origin and apostilled (or embassy attested for non-Hague Convention countries). Missing apostille is the single most common reason for registration delays
• Not budgeting for site inspection: CDSCO may require inspection of the foreign manufacturing facility. The foreign manufacturer bears all inspection costs including travel, accommodation, and per diem for CDSCO inspectors

Costs Summary: What to Budget

Integration with Other Regulatory Frameworks

The SUGAM portal does not operate in isolation. Foreign pharma and medical device companies must also navigate:

• FEMA compliance: FDI reporting through FC-GPR if setting up an Indian entity
• GST registration: Mandatory for import and sale of drugs and devices in India
• IEC (Import Export Code): Required before any import activity
• BIS certification: Certain electronic medical devices require Bureau of Indian Standards certification
• Customs clearance: Drugs and devices are subject to customs duty (basic customs duty ranges from 0-10% for pharma, 2.5-15% for medical devices) and require proper customs documentation
• FDI advisory: 100% FDI permitted under automatic route for greenfield pharma manufacturing; 74% automatic route for brownfield acquisitions

State Drug Licensing Authorities: The Other Regulatory Layer

While CDSCO handles national-level registrations and import licenses through SUGAM, foreign companies must also interact with State Drug Licensing Authorities (SDLAs) for certain approvals. State-level requirements include:

• Wholesale Drug License (Form 20B/21B): The Indian authorized agent must hold a valid wholesale license from the state where they operate. This license is issued by the State Drug Controller and is valid for 5 years
• Retail Sale License: If distributing directly to hospitals or retail pharmacies, a separate retail sale license from the SDLA is required
• Manufacturing License (Form 25/28): Foreign companies setting up manufacturing facilities in India need a state-level manufacturing license from the SDLA in addition to CDSCO approvals for specific products
• Blood Bank License: For companies importing blood products or diagnostics, state-level blood bank licenses may apply

The key distinction is that CDSCO (through SUGAM) handles product registration and import permissions, while SDLAs handle operational licenses for the entities physically present in India. A foreign pharma company typically needs both layers: CDSCO registration for the product and SDLA license for the entity importing or distributing it.

Quality Control Testing

CDSCO may require samples to be tested at government-approved laboratories before granting registration. The Central Drugs Laboratory (CDL) in Kolkata is the primary testing facility for drugs, while the Central Drugs Testing Laboratory (CDTL) handles medical devices. Testing fees range from INR 50,000 to INR 2,00,000 per product depending on the number of tests required. Results typically take 4-8 weeks, which should be factored into the overall registration timeline. Foreign companies should ensure product samples are shipped in compliance with Indian customs regulations, including proper labeling as "samples for testing -- not for sale" and relevant import documentation.

Key Takeaways

• The SUGAM portal (cdscoonline.gov.in) is the exclusive digital platform for all drug and medical device regulatory applications in India -- there is no offline alternative
• Foreign companies cannot apply directly; an Indian authorized agent with a valid drug/wholesale license must submit all applications and manage ongoing compliance
• Drug registration via Form 40 costs USD 10,000 per site plus USD 5,000 per drug, takes 9-12 months, and results in a 3-year Registration Certificate (Form 41)
• Medical device import license via Form MD-14 varies by device class, takes 6-18+ months, and results in a perpetually valid license (Form MD-15) that requires a retention fee every 5 years
• The 2026 query response rule rejects applications if queries go unanswered for 30 days -- designate a dedicated team member to monitor the portal daily